Intensity Therapeutics, Inc.
INTS
Rank in Stocks
#29210
Intensity Therapeutics, Inc. is a biotechnology enterprise in the clinical... Intensity Therapeutics, Inc. is a biotechnology enterprise in the clinical development phase, dedicated to discovering, advancing, and commercializing pharmaceutical treatments for solid tumor cancers. The company's primary experimental compound, INT230-6, is presently undergoing Phase 2 clinical trials. This investigational drug targets a range of difficult-to-treat solid tumors, including those affecting the pancreas, colon, bile duct, as well as squamous cell, sarcoma, breast, and liver cancers. Intensity Therapeutics has formed strategic collaborations with major pharmaceutical companies and research institutions: A partnership with Merck Sharpe & Dohme Corp. focuses on evaluating INT230-6 in conjunction with Keytruda for advanced pancreatic, colon, squamous cell, and bile duct malignancies. Another collaboration with Bristol-Myers Squibb Company is dedicated to studying INT230-6 combined with Yervoy in patients suffering from advanced liver, breast, and sarcoma cancers. Furthermore, the company is working with the Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research on a randomized controlled Phase II neoadjuvant study of INT230-6 for women diagnosed with early-stage breast cancer. Established in 2012, Intensity Therapeutics maintains its corporate headquarters in Westport, Connecticut.
Share Price
$3.15
Last synced: 2026-11-09
Market Cap
$8.51M
Change (1 day)
5.00%
Change (1 year)
-75.39%
Country
Stock data: Financial Modeling PrepยทUpdated ยทNot investment adviceยทHow we calculate this
Trade Intensity Therapeutics, Inc. (INTS)
Category
Healthcare
P/B ratio for Intensity Therapeutics, Inc. (INTS)
P/B ratio as of November 2026 TTM: 1.00
According to Intensity Therapeutics, Inc.'s latest financial reports and stock price, its current price-to-book ratio (TTM) is 1.00. At the end of 2025 the company had a P/B ratio of 1.17.
P/B ratio history for Intensity Therapeutics, Inc. from 2019 to 2026
P/B ratio at the end of each year
| Year | P/B Ratio | Change |
|---|---|---|
| 2026 (TTM) | 1.00 | -14.64% |
| 2025 | 1.17 | -86.03% |
| 2024 | 8.39 | 68.30% |
| 2023 | 4.98 | -470.23% |
| 2022 | -1.35 | -42.48% |
| 2021 | -2.34 | -82.05% |
| 2020 | -13.04 | -595.07% |
| 2019 | 2.63 | 0.00% |
P/B ratio for similar companies or competitors
| Company | P/B Ratio | P/B Ratio Difference | Country |
|---|---|---|---|
| 7.0081 | 601.72% |
US
|
|
| 12.9864 | 1,200.33% |
US
|
|
| 4.5726 | 357.86% |
AU
|
|
| 4.5877 | 359.37% |
BE
|
|
| 6.7286 | 573.74% |
NL
|
Questions about Intensity Therapeutics, Inc.'s P/B ratio
What is Intensity Therapeutics, Inc.'s P/B ratio?
Intensity Therapeutics, Inc.'s P/B ratio is 1.00, as of Nov 2026.
What was Intensity Therapeutics, Inc.'s P/B ratio in 2025?
In 2025, Intensity Therapeutics, Inc.'s P/B ratio was 1.17, compared with 8.39 in 2024.
How has Intensity Therapeutics, Inc.'s P/B ratio changed since 2020?
From 2020 to 2025, Intensity Therapeutics, Inc.'s P/B ratio was highest in 2024 (8.39) and lowest in 2020 (-13.04).
How does Intensity Therapeutics, Inc.'s P/B ratio compare with similar companies?
Intensity Therapeutics, Inc.'s P/B ratio (1.00) is lower than that of all 5 similar companies listed above. The highest among them is Moderna, Inc., with 12.99.